Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.26
GSK's Cash to Debt is ranked lower than
85% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.45 vs. GSK: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
GSK' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.48 Max: N/A
Current: 0.26
Equity to Asset 0.05
GSK's Equity to Asset is ranked lower than
97% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. GSK: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
GSK' s Equity to Asset Range Over the Past 10 Years
Min: 0.05  Med: 0.24 Max: 0.4
Current: 0.05
0.05
0.4
Interest Coverage 2.58
GSK's Interest Coverage is ranked lower than
85% of the 467 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.06 vs. GSK: 2.58 )
Ranked among companies with meaningful Interest Coverage only.
GSK' s Interest Coverage Range Over the Past 10 Years
Min: 0.81  Med: 9.42 Max: 24.87
Current: 2.58
0.81
24.87
F-Score: 4
Z-Score: 1.33
M-Score: -2.56
WACC vs ROIC
8.65%
7.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 7.46
GSK's Operating margin (%) is ranked lower than
53% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. GSK: 7.46 )
Ranked among companies with meaningful Operating margin (%) only.
GSK' s Operating margin (%) Range Over the Past 10 Years
Min: 1.68  Med: 28.24 Max: 34.91
Current: 7.46
1.68
34.91
Net-margin (%) 2.51
GSK's Net-margin (%) is ranked lower than
64% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. GSK: 2.51 )
Ranked among companies with meaningful Net-margin (%) only.
GSK' s Net-margin (%) Range Over the Past 10 Years
Min: 5.76  Med: 19.43 Max: 23.2
Current: 2.51
5.76
23.2
ROE (%) 11.14
GSK's ROE (%) is ranked higher than
64% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. GSK: 11.14 )
Ranked among companies with meaningful ROE (%) only.
GSK' s ROE (%) Range Over the Past 10 Years
Min: 17.3  Med: 61.93 Max: 84.96
Current: 11.14
17.3
84.96
ROA (%) 1.13
GSK's ROA (%) is ranked lower than
64% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. GSK: 1.13 )
Ranked among companies with meaningful ROA (%) only.
GSK' s ROA (%) Range Over the Past 10 Years
Min: 3.84  Med: 13.20 Max: 20.43
Current: 1.13
3.84
20.43
ROC (Joel Greenblatt) (%) 19.38
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.16 vs. GSK: 19.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GSK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.79  Med: 85.34 Max: 107.42
Current: 19.38
40.79
107.42
Revenue Growth (3Y)(%) -4.00
GSK's Revenue Growth (3Y)(%) is ranked lower than
76% of the 602 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. GSK: -4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GSK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4  Med: 4.85 Max: 15.3
Current: -4
-4
15.3
EBITDA Growth (3Y)(%) -18.20
GSK's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. GSK: -18.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GSK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.2  Med: 6.60 Max: 17.4
Current: -18.2
-18.2
17.4
EPS Growth (3Y)(%) -18.00
GSK's EPS Growth (3Y)(%) is ranked lower than
78% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. GSK: -18.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GSK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.3  Med: 4.95 Max: 51.3
Current: -18
-30.3
51.3
» GSK's 10-Y Financials

Financials (Next Earnings Date: 2016-07-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

GSK Guru Trades in Q2 2015

Diamond Hill Capital 169,372 sh (+80.61%)
Jim Simons 3,246,100 sh (+24.25%)
John Rogers 1,214,427 sh (+16.22%)
Sarah Ketterer 507,631 sh (+15.47%)
NWQ Managers 510,500 sh (+11.86%)
Charles Brandes 4,313,622 sh (+11.20%)
Pioneer Investments 1,326,663 sh (+9.74%)
Jeff Auxier 146,482 sh (+8.38%)
Ken Fisher 11,533,371 sh (+7.22%)
Murray Stahl 23,823 sh (+0.21%)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Kahn Brothers 58,200 sh (unchged)
Louis Moore Bacon 100,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
PRIMECAP Management 4,595,385 sh (-0.06%)
Tweedy Browne 128,285 sh (-2.33%)
Joel Greenblatt 80,157 sh (-4.09%)
HOTCHKIS & WILEY 11,615,471 sh (-5.59%)
Barrow, Hanley, Mewhinney & Strauss 252,300 sh (-6.87%)
Dodge & Cox 12,476,998 sh (-46.76%)
» More
Q3 2015

GSK Guru Trades in Q3 2015

John Rogers 1,458,162 sh (+20.07%)
Sarah Ketterer 606,315 sh (+19.44%)
Charles Brandes 4,673,082 sh (+8.33%)
Murray Stahl 25,723 sh (+7.98%)
HOTCHKIS & WILEY 12,400,884 sh (+6.76%)
Tweedy Browne 133,458 sh (+4.03%)
Jeff Auxier 148,507 sh (+1.38%)
First Eagle Investment 1 sh (unchged)
Francis Chou 18,000 sh (unchged)
Diamond Hill Capital 169,372 sh (unchged)
NWQ Managers 82,800 sh (unchged)
Ken Fisher 11,528,069 sh (-0.05%)
Kahn Brothers 57,500 sh (-1.20%)
Barrow, Hanley, Mewhinney & Strauss 249,000 sh (-1.31%)
PRIMECAP Management 4,265,385 sh (-7.18%)
NWQ Managers 462,055 sh (-9.49%)
Joel Greenblatt 51,451 sh (-35.81%)
Jim Simons 1,430,600 sh (-55.93%)
Pioneer Investments 582,121 sh (-56.12%)
Dodge & Cox 202,915 sh (-98.37%)
» More
Q4 2015

GSK Guru Trades in Q4 2015

Steven Cohen 87,100 sh (New)
Kahn Brothers 84,600 sh (+47.13%)
Murray Stahl 26,348 sh (+2.43%)
NWQ Managers 469,830 sh (+1.68%)
John Rogers 1,476,976 sh (+1.29%)
Joel Greenblatt 51,973 sh (+1.01%)
Ken Fisher 11,531,673 sh (+0.03%)
Barrow, Hanley, Mewhinney & Strauss 249,000 sh (unchged)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Tweedy Browne 133,124 sh (-0.25%)
PRIMECAP Management 4,250,285 sh (-0.35%)
HOTCHKIS & WILEY 12,102,919 sh (-2.40%)
Pioneer Investments 551,520 sh (-5.26%)
Diamond Hill Capital 160,031 sh (-5.52%)
Charles Brandes 4,303,030 sh (-7.92%)
Jeff Auxier 136,032 sh (-8.40%)
Sarah Ketterer 518,275 sh (-14.52%)
Dodge & Cox 112,782 sh (-44.42%)
Jim Simons 176,400 sh (-87.67%)
» More
Q1 2016

GSK Guru Trades in Q1 2016

Jeremy Grantham 79,900 sh (New)
Lee Ainslie 28,520 sh (New)
Jim Simons 480,600 sh (+172.45%)
Kahn Brothers 131,950 sh (+55.97%)
John Rogers 1,582,913 sh (+7.17%)
NWQ Managers 498,115 sh (+6.02%)
Charles Brandes 4,474,409 sh (+3.98%)
Barrow, Hanley, Mewhinney & Strauss 251,800 sh (+1.12%)
Ken Fisher 11,657,855 sh (+1.09%)
First Eagle Investment 1 sh (unchged)
Pioneer Investments 551,520 sh (unchged)
Francis Chou 18,000 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 51,331 sh (-1.24%)
Murray Stahl 25,973 sh (-1.42%)
Diamond Hill Capital 151,307 sh (-5.45%)
Tweedy Browne 116,070 sh (-12.81%)
Sarah Ketterer 450,405 sh (-13.10%)
Jeff Auxier 111,282 sh (-18.19%)
HOTCHKIS & WILEY 8,915,323 sh (-26.34%)
Dodge & Cox 81,262 sh (-27.95%)
PRIMECAP Management 1,116,885 sh (-73.72%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GLAXF.USA,
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

GlaxoSmithKline PLC was incorporated on 6 December 1999 in the United Kingdom. The Company creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led healthcare company that researches and develops products in three pharmaceutical areas, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatrics and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. It has products in four main categories: Oral care, Nutritional, Total wellness, and Skin health. Its brands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.

Guru Investment Theses on GlaxoSmithKline PLC

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Oct 17, 2014

We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Jun 26, 2014

Global pharmaceutical company GlaxoSmithKline PLC (GSK) has several attractive franchises and pipeline drug candidates that have the potential to add significant value.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Kahn Brothers Adds to BP, GlaxoSmithKline Stakes Firm founded by Irving Kahn adds to 8 holdings
Legendary investor Irving Kahn, along with his brothers Thomas Graham and Alan Kahn, founded the Kahn Brothers (Trades, Portfolio) Group in 1978, an investment firm that manages more than $800 million in assets. Irving Kahn trained directly with Benjamin Graham and served as his teaching assistant at Columbia Business School. Read more...
Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline Guru invests in stakes in UBS Group, Harley-Davidson
A team research approach guides Dodge & Cox’s investment decisions. The strategy works pretty well. Dodge & Cox enjoyed returns of more than 10% in 2014, which was good compared to many investors but modes compared to the returns from 2012 (22.01%) and 2013 (40.55%). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 111.77
GSK's P/E(ttm) is ranked lower than
91% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.44 vs. GSK: 111.77 )
Ranked among companies with meaningful P/E(ttm) only.
GSK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.35  Med: 14.71 Max: 119.52
Current: 111.77
6.35
119.52
Forward P/E 16.26
GSK's Forward P/E is ranked lower than
59% of the 90 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.95 vs. GSK: 16.26 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 111.77
GSK's PE(NRI) is ranked lower than
91% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.81 vs. GSK: 111.77 )
Ranked among companies with meaningful PE(NRI) only.
GSK' s PE(NRI) Range Over the Past 10 Years
Min: 6.38  Med: 14.73 Max: 115.85
Current: 111.77
6.38
115.85
Price/Owner Earnings (ttm) 31.96
GSK's Price/Owner Earnings (ttm) is ranked higher than
54% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.19 vs. GSK: 31.96 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GSK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.83  Med: 16.55 Max: 45.91
Current: 31.96
4.83
45.91
P/B 25.18
GSK's P/B is ranked lower than
98% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. GSK: 25.18 )
Ranked among companies with meaningful P/B only.
GSK' s P/B Range Over the Past 10 Years
Min: 5.48  Med: 9.12 Max: 26.1
Current: 25.18
5.48
26.1
P/S 2.89
GSK's P/S is ranked lower than
51% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. GSK: 2.89 )
Ranked among companies with meaningful P/S only.
GSK' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 2.81 Max: 4.22
Current: 2.89
1.94
4.22
PFCF 130.90
GSK's PFCF is ranked lower than
88% of the 199 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.71 vs. GSK: 130.90 )
Ranked among companies with meaningful PFCF only.
GSK' s PFCF Range Over the Past 10 Years
Min: 8.24  Med: 17.01 Max: 135.68
Current: 130.9
8.24
135.68
POCF 26.23
GSK's POCF is ranked lower than
64% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.71 vs. GSK: 26.23 )
Ranked among companies with meaningful POCF only.
GSK' s POCF Range Over the Past 10 Years
Min: 6.61  Med: 12.60 Max: 27.31
Current: 26.23
6.61
27.31
EV-to-EBIT 46.23
GSK's EV-to-EBIT is ranked lower than
84% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.64 vs. GSK: 46.23 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.60 Max: 48
Current: 46.23
6.3
48
EV-to-EBITDA 23.54
GSK's EV-to-EBITDA is ranked lower than
65% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.81 vs. GSK: 23.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
GSK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.10 Max: 24.5
Current: 23.54
5.6
24.5
Shiller P/E 14.59
GSK's Shiller P/E is ranked higher than
90% of the 146 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.77 vs. GSK: 14.59 )
Ranked among companies with meaningful Shiller P/E only.
GSK' s Shiller P/E Range Over the Past 10 Years
Min: 11.71  Med: 15.14 Max: 22.32
Current: 14.59
11.71
22.32
Current Ratio 1.14
GSK's Current Ratio is ranked lower than
84% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. GSK: 1.14 )
Ranked among companies with meaningful Current Ratio only.
GSK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.28 Max: 1.78
Current: 1.14
0.97
1.78
Quick Ratio 0.77
GSK's Quick Ratio is ranked lower than
86% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. GSK: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 0.99 Max: 1.42
Current: 0.77
0.68
1.42
Days Inventory 197.91
GSK's Days Inventory is ranked lower than
82% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. GSK: 197.91 )
Ranked among companies with meaningful Days Inventory only.
GSK' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 190.92 Max: 202.64
Current: 197.91
167.28
202.64
Days Sales Outstanding 89.44
GSK's Days Sales Outstanding is ranked lower than
59% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.15 vs. GSK: 89.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 74.32 Max: 93.9
Current: 89.44
54.62
93.9
Days Payable 128.20
GSK's Days Payable is ranked higher than
78% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.47 vs. GSK: 128.20 )
Ranked among companies with meaningful Days Payable only.
GSK' s Days Payable Range Over the Past 10 Years
Min: 62.75  Med: 333.04 Max: 372.4
Current: 128.2
62.75
372.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.42
GSK's Dividend Yield is ranked higher than
95% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. GSK: 5.42 )
Ranked among companies with meaningful Dividend Yield only.
GSK' s Dividend Yield Range Over the Past 10 Years
Min: 2.72  Med: 5.07 Max: 6.24
Current: 5.42
2.72
6.24
Dividend Payout 6.35
GSK's Dividend Payout is ranked lower than
59% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. GSK: 6.35 )
Ranked among companies with meaningful Dividend Payout only.
GSK' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.69 Max: 6.33
Current: 6.35
0.14
6.33
Dividend Growth (3y) 1.90
GSK's Dividend Growth (3y) is ranked lower than
64% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GSK: 1.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
GSK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -12.6  Med: 7.00 Max: 20.8
Current: 1.9
-12.6
20.8
Forward Dividend Yield 5.14
GSK's Forward Dividend Yield is ranked higher than
93% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. GSK: 5.14 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.50
GSK's Yield on cost (5-Year) is ranked higher than
94% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. GSK: 7.50 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GSK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.76  Med: 7.01 Max: 8.63
Current: 7.5
3.76
8.63
3-Year Average Share Buyback Ratio -2.00
GSK's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. GSK: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GSK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3  Med: 1.20 Max: 4.7
Current: -2
-20.3
4.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.03
GSK's Price/Projected FCF is ranked higher than
59% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. GSK: 2.03 )
Ranked among companies with meaningful Price/Projected FCF only.
GSK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.61 Max: 21.79
Current: 2.03
0.97
21.79
Price/Median PS Value 1.03
GSK's Price/Median PS Value is ranked higher than
56% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. GSK: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
GSK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.16 Max: 3.32
Current: 1.03
0.71
3.32
Earnings Yield (Greenblatt) (%) 2.20
GSK's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. GSK: 2.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GSK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 9.40 Max: 15.8
Current: 2.2
2.1
15.8
Forward Rate of Return (Yacktman) (%) 8.63
GSK's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 323 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.36 vs. GSK: 8.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GSK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4  Med: 12.80 Max: 40.6
Current: 8.63
4
40.6

More Statistics

Revenue (TTM) (Mil) $36,852
EPS (TTM) $ 0.38
Beta1.06
Short Percentage of Float0.20%
52-Week Range $37.24 - 45.49
Shares Outstanding (Mil)2,435.25

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 38,738 40,353 42,618
EPS ($) 2.72 2.80 3.00
EPS without NRI ($) 2.72 2.80 3.00
EPS Growth Rate
(3Y to 5Y Estimate)
2.51%
» More Articles for GSK

Headlines

Articles On GuruFocus.com
PhaseRX: The Latest Pick From a Legendary VC Firm May 24 2016 
Kahn Brothers Adds to BP, GlaxoSmithKline Stakes May 10 2016 
A Closer Look Into Veritas Pharma Apr 21 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Why the UK Is Headed For a Slowdown Mar 23 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Brandes Makes a Variety of Reductions in 4th Quarter Feb 11 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
Stocks Bring High Dividend Yields to HOTCHKIS & WILEY Jan 14 2016 
Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line Jan 04 2016 

More From Other Websites
Ionis Hits 3-Year Low As GlaxoSmithKline Drops Big Trial Plans May 26 2016
Ionis shares plummet as GSK scraps heart drug trial plans May 26 2016
[$$] Ionis's Shares Fall After Co-Developer Opts Against Starting Late-Stage Trial May 26 2016
Why Ionis Pharmaceuticals (IONS) Stock Is Tanking Today May 26 2016
Ionis Pharmaceuticals Inc (IONS) Plunges After GSK Foregos Phase 3 Study of TTRRx May 26 2016
Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta May 25 2016
Could the Worlds Most Effective Quit Smoking Aid be a Low Nicotine Cigarette US Public Health... May 25 2016
6:20 am GlaxoSmithKline, Fondazione Telethon, & Ospedale San Raffaele announce publication in BLOOD... May 25 2016
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and... May 25 2016
Is GlaxoSmithKline plc a better dividend buy than Standard Life plc and Legal & General Group plc? May 25 2016
Why this GSK news is good for workers in Zebulon May 24 2016
GSK lung drug succeeds in big UK study, after earlier miss May 24 2016
GSK lung drug succeeds in big UK study, after earlier miss May 24 2016
GSK lung drug succeeds in big UK study, after earlier miss May 24 2016
GSK lung drug succeeds in big UK study, after earlier miss May 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)